610791-05-4

610791-05-4 structure

Name: 1-BOC-AZETIDINE-3-CARBOXYLICACIDMETHYLESTER
Chemical Name: Methyl 1-Boc-azetidine-3-carboxylate
CAS Number: 610791-05-4
Molecular Formula: C₁₀H₁₇NO₄
Molecular Weight: 215.246
Catalog: Signaling Pathways Antibody-drug Conjugate ADC Linker
Create Date: 2019-01-01 10:48:56
Modify Date: 2024-01-05 13:44:23
Methyl 1-Boc-azetidine-3-carboxylate is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Methyl 1-Boc-azetidine-3-carboxylate is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1

Name	Methyl 1-Boc-azetidine-3-carboxylate
Synonyms	1-O-tert-butyl 3-O-methyl azetidine-1,3-dicarboxylate 1-BOC-AZETIDINE-3-CARBOXYLICACIDMETHYLESTER

Description	Methyl 1-Boc-azetidine-3-carboxylate is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Methyl 1-Boc-azetidine-3-carboxylate is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Antibody-drug Conjugate >> ADC Linker Signaling Pathways >> PROTAC >> PROTAC Linker
Target	Non-cleavable
In Vitro	ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1]. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].
References	[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337. [2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H302
Hazard Codes	Xi
RIDADR	NONH for all modes of transport
HS Code	2933990090

67-56-1

142253-55-2

~99%

610791-05-4

Literature: PFIZER INC. Patent: WO2006/21881 A2, 2006 ; Location in patent: Page/Page column 61 ; WO 2006/021881 A2

142253-55-2

18107-18-1

~98%

610791-05-4

Literature: AGOURON PHARMACEUTICALS, INC. Patent: US2006/46991 A1, 2006 ; Location in patent: Page/Page column 55-56 ; US 20060046991 A1

100202-39-9

24424-99-5

~14%

610791-05-4

Literature: Eisai RandD Management Co., Ltd. Patent: US2008/214815 A1, 2008 ; Location in patent: Page/Page column 15 ;

HS Code	2933990090
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%